Ongoing Studies:
Vertex Pharmaceuticals Incorporated/ A Phase 2/3 Adaptive, Double-blind, PlaceboControlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 12 Years and Older With APOL1-mediated Proteinuric Kidney Disease (Sponsor: Vertex)
A Multicenter, Double blind, Randomized, Placebo Controlled parallel group, phase 2 study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients (Sponsor: Novartis)
A Randomized, Double-Blind, Placebo Controlled Sequential, Parallel Arm, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of MLS-101 in Subjects with Uncontrolled Hypertension on a Standardized Medication Regimen. Protocol Number: MLS-101-202 (Sponsor: Caidya)
A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Pre-exposure Prophylaxis of COVID-19.
Application of Cell-free DNA in Kidney Transplant Patients in the Local Community Nephrology Clinics – IIT.
Transition of Renal Patients using Allosure into Community Kidney Care – TRACK.
Role of Intermittent Pneumatic Compression Device in increasing vein diameter in Patients with Kidney Disease requiring Arteriovenous Fistulas.
Evaluate Post-transplant Clinical Outcomes in Recipients of Kidney Transplants who are undergoing TruGraf and TRAC monitoring.
A Phase-2, Double-blind, Placebo-controlled, Dose-ranging Study to evaluate the efficacy, safety, and pharmacokinetics of VK-147.
The Nephrology Group – TNG002, Antibody Level Post Vaccination in End-Stage Renal Disease and Kidney Transplant Patients. Am I really Immune?
The Nephrology Group – TNG003, Antibody Level’s Post-2nd Vaccination in Frontline Health Care Workers. Am I Still Protected?
The Nephrology Group – TNG004, Antibody Levels in patients infected with COVID-19 prior to infusion with monoclonal antibodies.
A Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of LCZ696 Compared to Valsartan on Cognitive Function in Patients with Chronic Heart Failure and Preserved Ejection Fraction.
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion form a Long-acting Erythropoiesis-stimulating agent (MIRCERA) to Three Times Weekly Oral VADUSTAT for the Maintenance Treatment of Anemia in Hemodialysis Subjects.
A Randomized, Controlled, Multicenter, Open-label trial comparing a Hospital Post-Discharge Care Pathway involving aggressive LDL-C management that includes INCLISIRAN with Usual Care Versus Usual Care alone in Patients with a Recent Acute Coronary Syndrome.